We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Alkemy Capital Investments Plc | LSE:ALK | London | Ordinary Share | GB00BMD6C023 | ORD GBP0.02 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 87.50 | 85.00 | 90.00 | 90.00 | 87.50 | 90.00 | 2,726 | 08:00:43 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Offices-holdng Companies,nec | 0 | -2.65M | -0.3239 | -2.70 | 7.14M |
TIDMALK TIDMB
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that based on a strong sales momentum and the outlook for the remainder of the year, ALK has upgraded its full-year outlook. As a result:
Hot Features
Premium
-- Revenue is now expected to grow 10-13% in local currencies (previously:
8-12%).
-- EBITDA is now expected to increase to DKK 675-750 million (previously:
625-725).
ALK will publish its Q2 performance in connection with the six-month interim report on 11 August 2022.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014
This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
-- FM_13_22UK_04082022
https://ml-eu.globenewswire.com/Resource/Download/d153a6d0-5efc-4acb-9c8d-d2bbaa39eac9
(END) Dow Jones Newswires
August 04, 2022 07:37 ET (11:37 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Alkemy Capital Investments Chart |
1 Month Alkemy Capital Investments Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
